Skip to main content
NASDAQ:INSM

Insmed Competitors

$26.82
-0.14 (-0.52 %)
(As of 05/12/2021 03:39 PM ET)
Add
Compare
Today's Range
$26.54
$27.97
50-Day Range
$25.99
$37.59
52-Week Range
$22.67
$45.44
Volume84,872 shs
Average Volume1.08 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.43

Competitors

Insmed (NASDAQ:INSM) Vs. JAZZ, BHC, MRVI, UTHR, MRTX, and BBIO

Should you be buying INSM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Insmed, including Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Maravai LifeSciences (MRVI), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), and BridgeBio Pharma (BBIO).

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.62$523.37 million$14.6012.03
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91

Jazz Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jazz Pharmaceuticals and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Insmed-145.14%-79.58%-31.14%

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Jazz Pharmaceuticals and Insmed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111502.82
Insmed00703.00

Jazz Pharmaceuticals currently has a consensus target price of $192.6250, suggesting a potential upside of 9.09%. Insmed has a consensus target price of $53.5714, suggesting a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Insmed on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Bausch Health Companies and Insmed, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies13502.44
Insmed00703.00

Bausch Health Companies currently has a consensus target price of $34.80, suggesting a potential upside of 25.13%. Insmed has a consensus target price of $53.5714, suggesting a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Bausch Health Companies.

Profitability

This table compares Bausch Health Companies and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Insmed-145.14%-79.58%-31.14%

Valuation & Earnings

This table compares Bausch Health Companies and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.16$-1,788,000,000.00$4.436.28
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91

Insmed has lower revenue, but higher earnings than Bausch Health Companies. Insmed is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Bausch Health Companies beats Insmed on 8 of the 14 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Insmed and Maravai LifeSciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed00703.00
Maravai LifeSciences001003.00

Insmed currently has a consensus target price of $53.5714, indicating a potential upside of 100.42%. Maravai LifeSciences has a consensus target price of $38.3750, indicating a potential upside of 6.21%. Given Insmed's higher possible upside, equities analysts plainly believe Insmed is more favorable than Maravai LifeSciences.

Profitability

This table compares Insmed and Maravai LifeSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-145.14%-79.58%-31.14%
Maravai LifeSciencesN/AN/AN/A

Valuation & Earnings

This table compares Insmed and Maravai LifeSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91
Maravai LifeSciencesN/AN/AN/AN/AN/A

Maravai LifeSciences has lower revenue, but higher earnings than Insmed.

Summary

Maravai LifeSciences beats Insmed on 4 of the 6 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and United Therapeutics (NASDAQ:UTHR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

90.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Comparatively, 10.9% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Insmed and United Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91
United Therapeutics$1.45 billion6.06$-104,500,000.00($2.39)-82.05

United Therapeutics has higher revenue and earnings than Insmed. United Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Insmed and United Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Insmed-145.14%-79.58%-31.14%
United Therapeutics33.25%15.48%11.31%

Analyst Recommendations

This is a breakdown of recent ratings for Insmed and United Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Insmed00703.00
United Therapeutics00703.00

Insmed currently has a consensus target price of $53.5714, indicating a potential upside of 100.42%. United Therapeutics has a consensus target price of $227.1429, indicating a potential upside of 15.79%. Given Insmed's higher possible upside, equities analysts plainly believe Insmed is more favorable than United Therapeutics.

Risk & Volatility

Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

United Therapeutics beats Insmed on 9 of the 12 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Mirati Therapeutics and Insmed's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirati Therapeutics$3.34 million2,365.16$-213,260,000.00($5.69)-26.99
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91

Mirati Therapeutics has higher earnings, but lower revenue than Insmed. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirati Therapeutics and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirati TherapeuticsN/A-60.01%-54.21%
Insmed-145.14%-79.58%-31.14%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mirati Therapeutics and Insmed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirati Therapeutics141002.60
Insmed00703.00

Mirati Therapeutics presently has a consensus price target of $225.2308, indicating a potential upside of 46.38%. Insmed has a consensus price target of $53.5714, indicating a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Mirati Therapeutics.

Risk and Volatility

Mirati Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Summary

Insmed beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

BridgeBio Pharma (NASDAQ:BBIO) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BridgeBio Pharma and Insmed, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BridgeBio Pharma01902.90
Insmed00703.00

BridgeBio Pharma presently has a consensus price target of $71.6667, indicating a potential upside of 44.64%. Insmed has a consensus price target of $53.5714, indicating a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than BridgeBio Pharma.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares BridgeBio Pharma and Insmed's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Pharma$40.56 million182.00$-260,590,000.00($2.48)-19.94
Insmed$136.47 million20.34$-254,340,000.00($3.01)-8.91

Insmed has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Profitability

This table compares BridgeBio Pharma and Insmed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BridgeBio PharmaN/A-109.88%-48.54%
Insmed-145.14%-79.58%-31.14%

Summary

Insmed beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.


Insmed Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$175.59-1.0%$9.89 billion$2.16 billion55.39Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$27.80-1.3%$9.83 billion$8.60 billion-5.10
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.11-2.1%$9.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$196.10-0.9%$8.70 billion$1.45 billion18.55Earnings Announcement
Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$153.57-2.0%$7.74 billion$3.34 million-19.94Earnings Announcement
Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$49.45-0.6%$7.33 billion$40.56 million-14.50Earnings Announcement
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$106.84-1.5%$7.32 billion$103.71 million-24.34Analyst Report
Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.66-1.7%$7.27 billion$87.99 million-81.74Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$136.48-2.1%$7.18 billion$14.98 million-16.62Upcoming Earnings
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.55-2.7%$5.92 billion$4.84 billion-759.04Earnings Announcement
Unusual Options Activity
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.90-3.9%$5.67 billion$380.83 million-9.45Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$92.12-1.8%$5.47 billion$66.51 million17.00
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$36.60-2.5%$5.31 billion$150,000.00-17.26Earnings Announcement
Unusual Options Activity
Allakos logo
ALLK
Allakos
1.7$99.02-0.1%$5.30 billionN/A-36.14Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.17-1.3%$5.17 billion$1.12 billion77.44Earnings Announcement
Analyst Report
Galapagos logo
GLPG
Galapagos
1.3$73.96-0.5%$4.82 billion$1.00 billion-11.21Analyst Report
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.32-3.1%$4.37 billionN/A-5.57Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.42-0.3%$4.34 billion$6.87 million-7.19Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.87-3.1%$4.32 billion$85.54 million0.00Analyst Report
News Coverage
I-Mab logo
IMAB
I-Mab
1.2$61.65-4.7%$4.25 billion$4.31 million-2.13
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.35-3.4%$3.93 billion$117.91 million-11.02
LEGN
Legend Biotech
1.3$30.25-2.4%$3.93 billion$64.39 million0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.26-2.3%$3.80 billion$806.43 million-8.68Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$24.50-4.2%$3.80 billion$204.89 million-30.63
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.24-0.9%$3.75 billionN/A-6.23
Alkermes logo
ALKS
Alkermes
1.2$22.38-0.2%$3.58 billion$1.17 billion-48.65
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.58-3.8%$3.52 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.89-0.6%$3.39 billionN/A-57.66Earnings Announcement
Analyst Revision
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.82-4.5%$3.34 billion$339.08 million-12.69Analyst Report
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$66.40-2.2%$3.19 billionN/A-18.92Earnings Announcement
Analyst Upgrade
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.68-0.2%$3.15 billion$1.11 billion18.87Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$37.72-1.6%$3.01 billion$60,000.00-11.71Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.68-1.7%$3.01 billion$26.52 million-7.20Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$63.33-3.2%$3.00 billion$42.98 million-24.74
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$71.99-0.3%$2.76 billion$644.77 million-10.27Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.13-1.6%$2.73 billion$306.98 million-5.45
MorphoSys logo
MOR
MorphoSys
0.3$20.11-1.2%$2.68 billion$80.43 million95.77News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$62.00-2.1%$2.67 billion$421.03 million21.83Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.60-1.1%$2.60 billionN/A-22.86Earnings Announcement
Gap Up
Cryoport logo
CYRX
Cryoport
1.7$51.76-9.3%$2.58 billion$33.94 million-89.24Analyst Report
Analyst Revision
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.18-4.6%$2.55 billion$182.24 million-7.98Earnings Announcement
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.81-2.3%$2.49 billionN/A0.00
ALX Oncology logo
ALXO
ALX Oncology
1.9$55.37-9.4%$2.44 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.57-0.6%$2.39 billion$306.49 million23.11Earnings Announcement
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.72-2.9%$2.35 billion$2.11 million-7.95Analyst Report
Analyst Revision
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$46.38-1.6%$2.35 billion$963.01 million14.40Earnings Announcement
Analyst Report
Analyst Revision
Organogenesis logo
ORGO
Organogenesis
1.0$17.18-4.3%$2.30 billion$260.98 million-286.33Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$3.34-2.4%$2.29 billion$901.90 million-18.55Insider Buying
Xencor logo
XNCR
Xencor
1.6$37.68-2.5%$2.25 billion$156.70 million-26.91Earnings Announcement
Analyst Report
Analyst Revision
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.